Enochian Biosciences' Cancer Platform on Track for Human Trials by 2024
Enochian Biosciences has announced that its innovative Cancer Platform is expected to undergo clinical trials in humans during the first half of 2024. The US Food and Drug Administration (FDA) recently confirmed this after reviewing Enochian's Pre-Investigational New Drug Application submission. The company’s technology uses cell- and gene-therapy to promote renewed immune responses against solid tumors, which may have potential use against triple-negative breast cancer, oral cancers, mesothelioma, and other solid tumors. Dr. Anahid Jewett at UCLA independently confirmed the effectiveness of the platform using humanized mouse models in which there was a significant infiltration of key immune cells in mice treated with cell-and-gene therapy with very little tumor remaining.
The initial studies were conducted on a pancreatic cancer mouse model developed by Dr. Jewett’s laboratory and presented previously at two scientific conferences*. According to Dr. Jewett: “There was a significant infiltration of key immune cells in mice treated with the cell- and gene-therapy with very little tumor remaining…These are among some of the most promising results that we have seen working in this field."
CEO Mark Dybul expressed gratitude to FDA for